Sinovac Announces Management Changes
BEIJING, Aug. 5, 2011 /PRNewswire-Asia/ -- *Sinovac Biotech Ltd.* (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today the resignation of Jacob Chik Keung Ho, its Chief Financial Officer, for personal reasons. The Company has initiated an executive search for a n...
Sinovac to Host Conference Call to Report Second Quarter 2011 Unaudited Financial Results
BEIJING, Aug. 1, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccines in China, today announced that it will release its unaudited financial results for the second quarter ended June 30, 2011 before market on Friday, August 12, 2011. The Company will host a co...
Sinovac Holds 2011 Annual Shareholders Meeting
BEIJING, July 14, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that it held its 2011 Annual Shareholders Meeting on Thursday, July 14, 2011 at 9:00 a.m. Beijing Time. The required quorum, a majority of the co...
Sinovac Schedules 2011 Annual Meeting of Shareholders
BEIJING, June 7, 2011 / PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading developer and provider of vaccines in China, announced today that it will hold its 2011 Annual Meeting of Shareholders on Thursday, July 14, 2011 at 9:00 a.m. Beijing Time. The meeting will be held concurrently...
Sinovac Appoints Kenneth Lee to Board of Directors
BEIJING, May 31, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today the appointment of Mr. Kenneth Lee as a director to the Board of the Company effective on May 31, 2011 to replace Mr. Xianping Wang who resigned f...
Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD)
- Unblinded Results for Children and Infant Groups Show Good Safety Profile Following Previously Announced Positive Adult Group Results - BEIJING, May 25, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA - News), a leading provider of biopharmaceutical products in China, announced today ...
Sinovac Reports Unaudited First Quarter 2011 Financial Results
- Conference call scheduled for Friday, May 13, 2011 at 8:00 AM EDT – BEIJING, May 13, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited first quarter financial results for the period ended Ma...
Sinovac Presents at Two Investor Conferences in May 2011
BEIJING, May 9, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that Mr. Jacob Ho, Chief Financial Officer, and Ms. Helen Yang, Investor Relations Manager, are scheduled to present at two upcoming investor confe...
Sinovac to Host Conference Call to Report First Quarter 2011 Unaudited Financial Results
BEIJING, May 3, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccines in China, today announced that it will release its unaudited financial results for the first quarter ended March 31, 2011 before market on Friday, May 13, 2011. The Company will host a confe...
Sinovac Files Annual Report on Form 20-F
BEIJING, April 23, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today it has filed its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2010 on April 22, 2...
Sinovac Reports Fourth Quarter and Full Year 2010 Financial Results
- Conference call scheduled for Thursday, March 31, 2011 at 8:00 AM EDT – BEIJING, March 31, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today its fourth quarter and full year financial results periods ended...
Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2010 Audited Financial Results
BEIJING, March 28, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccines in China, today announced that it will release its audited financial results for the fourth quarter and full year ended December 31, 2010 before market on Thursday, March 31, 2011. The Co...
Sinovac Participates in UBS Greater China Healthcare Corporate Day
BEIJING, March 25, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that Dr. Weidong Yin, President and CEO, and Ms. Helen Yang, Investor Relations Manager, are scheduled to participate in the UBS Greater China H...
Sinovac Reports Positive Preliminary Phase I Clinical Trial Results for EV71 Vaccine in Adult Group
Unblinded Results Show Good Safety Profile and Preliminary Immunogenicity BEIJING, March 10, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today the unblinding of the Phase I clinical trial results for the adult po...
Sinovac Biotech Submits Clinical Trial Application to SFDA for Pneumococcal Conjugate Vaccine (PCV)
-Completes Pre-Clinical Studies- BEIJING, March 3, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today it submitted the application to commence clinical trials for its 13-valent pneumococcal conjugate vaccine (PCV)...
Sinovac Presents at Rodman & Renshaw Annual China Investment Conference
BEIJING, March 1, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that Mr. Jacob Ho, Acting Chief Financial Officer, Ms. Helen Yang, Investor Relations Manager, and Ms. Chris Lee, Investor Relations, are schedul...
Sinovac Biotech Files Clinical Trial Applications with SFDA for its Proprietary Pneumococcal Polysaccharides Vaccines (PPV)
-Completes Pre-Clinical Studies- BEIJING, Jan. 31, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today the submission of the applications to commence human clinical trials for its 23-valent and 24-valent pneumococc...
Sinovac Participates in UBS Greater China Conference 2011
BEIJING, Jan. 11, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that Mr. Jacob Ho, Acting Chief Financial Officer, Ms. Helen Yang, Investor Relations Manager, and Ms. Chris Lee, Investor Relations, are schedul...
Sinovac Provides Preliminary Unaudited Fourth Quarter 2010 Sales Range
BEIJING, Jan. 6, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today its preliminary unaudited sales range for the fourth quarter and full year ended December 31, 2010. A conference call to discuss these preliminary...